share_log

Investors Can Find Comfort In China Medical System Holdings' (HKG:867) Earnings Quality

Investors Can Find Comfort In China Medical System Holdings' (HKG:867) Earnings Quality

投資者可以在中國醫療系統控股(HKG:867)的盈利質量中找到安慰
Simply Wall St ·  09/06 18:07

The market was pleased with the recent earnings report from China Medical System Holdings Limited (HKG:867), despite the profit numbers being soft. Our analysis suggests that investors may have noticed some promising signs beyond the statutory profit figures.

儘管利潤數字疲軟,但市場對中國醫療控股有限公司(HKG: 867)最近的收益報告感到滿意。我們的分析表明,除了法定利潤數字外,投資者可能已經注意到一些令人鼓舞的跡象。

big
SEHK:867 Earnings and Revenue History September 6th 2024
SEHK: 867 收益和收入歷史記錄 2024 年 9 月 6 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

Importantly, our data indicates that China Medical System Holdings' profit was reduced by CN¥233m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect China Medical System Holdings to produce a higher profit next year, all else being equal.

重要的是,我們的數據表明,由於異常項目,中國醫療系統控股的利潤比去年減少了23300萬元人民幣。儘管由於不尋常項目而產生的扣除首先令人失望,但有一線希望。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。鑑於這些單列項目被認爲不尋常,這並不奇怪。假設這些不尋常的支出不會再次出現,因此,在其他條件相同的情況下,我們預計中國醫療控股公司明年將實現更高的利潤。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On China Medical System Holdings' Profit Performance

我們對中醫控股盈利表現的看法

Unusual items (expenses) detracted from China Medical System Holdings' earnings over the last year, but we might see an improvement next year. Because of this, we think China Medical System Holdings' earnings potential is at least as good as it seems, and maybe even better! On the other hand, its EPS actually shrunk in the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 2 warning signs for China Medical System Holdings and you'll want to know about these.

去年,不尋常的項目(支出)減少了中國醫療控股的收益,但明年我們可能會看到改善。正因爲如此,我們認爲中醫控股的盈利潛力至少和看上去一樣好,甚至可能更好!另一方面,其每股收益實際上在過去十二個月中萎縮了。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。請記住,在分析股票時,值得注意所涉及的風險。你可能會有興趣知道,我們發現了中國醫療控股公司的兩個警告信號,你會想知道這些信號的。

This note has only looked at a single factor that sheds light on the nature of China Medical System Holdings' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這份報告只研究了揭示中醫控股利潤性質的單一因素。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 「關注資金」,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份擁有大量內幕持股的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論